{
  "id": "mhgap#risk_safety_39ab4c70",
  "content": "3. Recommendations\ny There is low- to moderate-quality evidence that Research gaps\nthe safety profile of levetiracetam was better y Most of the research is from HICs. Further studies are\nthan fosphenytoin in terms of less requirement needed in LMICs.\nfor intubation.\ny Further research is needed on the proportion of\ny There is low- to moderate-quality evidence that electrographic seizures after resolution of clinical\nthe safety profile of sodium valproate was better seizures in status epilepticus with different ASMs\nthan phenytoin for cardiovascular adverse effects, in children.\nand better than fosphenytoin in terms of less\ny As the outcome is highly dependent on the etiology\nrequirement for intubation.\nof status epilepticus, trials in adults/children with\ny The advantages of sodium valproate include a status epilepticus of specific etiology, such as\nsmaller risk for cardiorespiratory side-effects. infectious etiology (e.g. encephalitis), may be useful\ny Sodium valproate has, however, been associated to improve understanding.\nwith risks for hepatotoxicity and pancreatitis. It is\ncontraindicated in individuals with liver disease, Implementation considerations\nwhich may not be evident when the person is y The choice of medicine is affected by a number of",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "risk_safety"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Risk Safety 3. Recommendations\ny There is low- to moderate-quality evidence that Research gaps\nthe safety profile of levetiracetam was better y Most of the research is from HICs. Further studies are\nthan fosphenytoin in terms of less requirement needed in LMICs.\nfor intubation.\ny Further research is needed on the proportion of\ny There is low- to moderate-quality evidence that electrographic seizures after resolution of clinical\nthe safety profile of sodium valproate was better seizures in status epilepticus with different ASMs\nthan phenytoin for cardiovascular adverse effects, in children.\nand better than fosphenytoin in terms of less\ny As the outcome is highly dependent on the etiology\nrequirement for intubation.\nof status epilepticus, trials in adults/children with\ny The advantages of sodium valproate include a status epilepticus of specific etiology, such as\nsmaller risk for cardiorespiratory side-effects. infectious etiology (e.g. encephalitis), may be useful\ny Sodium valproate has, however, been associated to improve understanding.\nwith risks for hepatotoxicity and pancreatitis. It is\ncontraindicated in individuals with liver disease, Implementation considerations\nwhich may not be evident when the person is y The choice of medicine is affected by a number of 3. recommendations\ny there is low- to moderate-quality evidence that research gaps\nthe an toàn profile of levetiracetam was better y most of the research is from hics."
}